Jupiter Neurosciences Secures $100M Term Sheet for U.S. Rights to PharmAla’s MDMA Therapy ALA-002
Transaction Positions JUNS as a Leader in MDMA Therapeutics Following Trump’s Psychedelic Medicine Executive Order Jupiter Neurosciences, Inc. (NASDAQ:JUNS) JUPITER, FL, UNITED STATES, May 20, 2026 /EINPresswire.com/ -- Jupiter Neurosciences, …